WO2003100058A2 - Verfahren zur erzeugung von polynukleotidmolekülen - Google Patents
Verfahren zur erzeugung von polynukleotidmolekülen Download PDFInfo
- Publication number
- WO2003100058A2 WO2003100058A2 PCT/EP2003/005308 EP0305308W WO03100058A2 WO 2003100058 A2 WO2003100058 A2 WO 2003100058A2 EP 0305308 W EP0305308 W EP 0305308W WO 03100058 A2 WO03100058 A2 WO 03100058A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotide molecules
- stranded polynucleotide
- double
- error rate
- strand breaks
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Definitions
- the present invention relates to a method for producing polynucleotide molecules with modified properties.
- Biomolecules - and especially biopolymers such as polynucleotides, polypeptides, polysaccharides etc. - are not only the basis of the biological life known to us, but are also increasingly being used in a wide variety of technical fields of application.
- the search for new functional biomolecules, their isolation or production, as well as their technical application is the subject of modern biotechnology.
- methods have been used for some time that follow the principles of natural evolution in the laboratory.
- the recombination of sequence sections in nature represents a very successful strategy for the combination of punctual mutations, but also of domains within a polymer, of subunits of a heteromultimer, or of gene variants within a gene cluster or of genes within a genome.
- homologous recombination ie The combination of corresponding sequence sections from different variants while maintaining orientation and reading frame is of great importance.
- Recombination can be realized experimentally in different ways: on the one hand in vitro using individual enzyme functions or defined mixtures or sequences of enzymatic processing steps, on the other hand in vivo using cellular recombination and / or repair processes.
- DNA shuffling also known as secual PCR
- Any gene fragments that overlap in their sequence are generated and then reconstructed into products of the original length by PCR without addition of primer.
- fragments of different origins can happen to be homologous to a product molecule in each PCR cycle get connected.
- DNA shuffling basically allows you to limit the frequency of recombination events.
- this method is experimentally complex, since the reaction conditions for generating the nucleic acid fragments must first be established.
- a method which generates heteroduplexes from a population of polynucleotide sequences with mutations, which are then subjected to statistical repair in vivo by insertion into cells or in vitro by incubation with a cell extract, depending on the method relative frequency of the variants in the starting population to a certain extent recombined molecular variants arise (WO 99/29902).
- This method is characterized by the use of cellular repair systems that specifically recognize unpaired bases and statistically repair one of the two strands in the double strand.
- the limitation of this method lies on the one hand in the limited efficiency in introducing polynucleotides into cells and in the lack thereof
- a further disadvantage is that only two starting molecules can be recombined with each other in one repair step.
- the present invention is therefore based on the object of making available a method for producing polynucleotides with modified properties, which the above avoids the disadvantages of the known methods described and which allows an efficient recombination of genotypes of polynucleotide molecules and which thus leads to the generation of changed phenotypes.
- the present invention thus relates to a method for producing polynucleotide molecules with modified properties, at least one cycle comprising the following steps:
- steps (b) and (c) can be carried out sequentially or simultaneously.
- the method according to the invention is thus characterized by a combination of advantages which cannot be achieved with any of the methods described so far.
- the low experimental and time expenditure of the method and the possibility of automation are further advantages.
- the method according to the invention is characterized in that by simultaneous nucleolytic degradation and nucleic acid synthesis; The so-called nick translation thus prevents both excessive fragmentation of the nucleic acids and the degradation of recombinant nucleic acids.
- the total amount of DNA used is in principle available for the subsequent recombination of the nucleic acids in vitro.
- the efficiency of the recombination can thus be increased in vitro compared to the methods for recombining nucleic acids described so far.
- more than one cycle comprising steps (a) through (d) above, i.e. at least two, preferably at least 5, particularly preferably at least 10 and very particularly preferably at least 20.
- polynucleotides with multiple newly combined sequence regions can be produced from an initial distribution of related polynucleotide sequences.
- the cyclical application allows several different heterologous sequence sections to be combined with one another.
- the number of cycles allows the frequency of recombination per strand of polynucleotide to be precisely controlled.
- the average distance between recombination events from one cycle to the next can also be controlled.
- a selection step is carried out after one, several or all cycles of the method according to the invention. This can refer to either the genotype or the phenotype or both the genotype and the phenotype of the polynucleotide.
- the genotype of a polynucleotide is the sequential sequence of different monomers in the polynucleotide.
- the phenotype is the sum of the functions and properties of a polynucleotide molecule and the transcription or translation products encoded by a polynucleotide.
- the selection step can take place, for example, in the form of amplification-coupled (natural) selection, selection by physical separation or selection by screening (Koltermann and Kettling, Biophys. Chem. 66 (1999), 159; Kettling et al. Current Topics in Microbiol. and Immunol. 243 (1999), 173; Koltermann, Dissertation, TU Berlin (1998), Zhao et al. in Manual of Ind. Microbiol. and Biotechnol. Chapter 49, pp. 597604, ASM Press, Washington, DC, 1999; Reetz, Angew. Chem. 113 (2001) 113, 292-320.
- step (a) of the method according to the invention a double-stranded polynucleotide molecule or a population of double-stranded polynucleotide molecules is provided.
- the population of double-stranded polynucleotide molecules provided according to step (a) of the method according to the invention can be any population of double-stranded polynucleotide molecules which comprises at least two types of polynucleotide molecules, these comprising at least one homologous sequence section and at least one heterologous sequence section.
- the term “population of single-stranded polynucleotide molecules” denotes a set of polynucleotide molecules, intermolecular interactions in the form of specific base pairings between the molecules being prevented or not existing.
- polynucleotides includes both DNA and RNA, polynucleotides are linear, oriented (5 '- + 3' direction) heteropolymers, which can be single-stranded or double-stranded. In the double strand, two single strands are bound together by interactions in the form of specific base pairing.
- the polynucleotides can also be DNA or RNA with modified monomers. In general, the method can also be applied to analogue, artificial polymers and to DNA-RNA hybrid double rods.
- homologous sections refers to sections that are identical or complementary on two or more polynucleotide molecules, i.e. have the same information at the corresponding position.
- heterologous sections refers to sections that are not identical or not complementary on two or more polynucleotide molecules, i.e. have different information at the corresponding position.
- Information of a polynucleotide molecule denotes the sequential sequence of different monomers in a polynucleotide molecule.
- a heterologous sequence region has a length of at least one nucleotide, but can also be considerably longer.
- a heterologous sequence region can have a length of two nucleotides, or of three nucleotides, for example of codon, and preferably of more than 5 nucleotides, particularly preferably of more than 10 nucleotides. In principle, there is no limit to the length of a heterologous area. However, a heterologous region should preferably not be longer than 10,000 nucleotides, particularly preferably not longer than
- Such longer sequence sections can be, for example, the hypervariable regions of a sequence coding for an antibody. Domains of a protein, genes in a gene cluster or regions of a genome.
- the heterologous regions are preferably sequence regions in which the polynucleotide molecules differ from one another in individual bases. However, heterologous areas can also be based on the fact that deletion, duplication, insertion, inversion or addition is present or has occurred in a polynucleotide molecule.
- the double-stranded polynucleotide molecules provided according to step (a) of the method according to the invention have at least one homologous and at least one heterologous sequence region according to the invention. However, they preferably have a large number of homologous and heterologous sections. In principle there is no upper limit to the number of homologous and heterologous sections.
- the homologous sections have a length of preferably at least 5, preferably at least 10 and particularly preferably at least 20 nucleotides. Like the heterologous sections, the homologous sections can be much longer and there is in principle no upper limit for their length. They should preferably be no longer than 50,000 nucleotides, preferably no longer than 20,000 nucleotides, particularly preferably no longer than 10,000 nucleotides and very particularly preferably no longer than 1000 nucleotides.
- Double-stranded polynucleotide molecules according to step (a) of the method according to the invention can be provided by methods known to the person skilled in the art. These include e.g. physical, chemical, biochemical and biological processes. These include both synthetic and preparative processes such as chemical synthesis of oligonucleotides, synthesis of nucleic acids by polymerase chain reaction (PCR), preparation of plasmids, cosmids, phages, BACs (bacterial artificial chromosomes), YACs (yeast artificial chromosomes) or chromosomal DNA.
- PCR polymerase chain reaction
- polynucleotide sequences from the mutant distribution of a quasi-species are used to provide a population of double-stranded polynucleotides with homologous and heterologous sections.
- the term “related” relates to polynucleotides that are both homologous to one another as well as having heterologous sections.
- a quasi-species is a dynamic population of mutually related molecular variants (mutants) resulting from faulty replication. It could be shown that according to the quasi-species principle, it is not the wild type (focus of the quasi-species), but the entire distribution that is the object of the selection.
- the basis for the generation of a quasi-species is an incorrect replication of the molecular variants.
- replication is preferably carried out with the aid of replication enzymes, i.e. Polymerases that enable the template-controlled synthesis of a polynucleotide molecule.
- the introduction of errors, i.e. The variation of the molecular information can be caused by the inherently faulty copying process alone, but also by a targeted increase in the inaccuracy of the polymerase (e.g.
- phenotype of a polynucleotide molecule denotes the sum of the functions and properties of a polynucleotide molecule and the transcription or translation products encoded by a polynucleotide.
- sequences of different origins can be used, including polynucleotide sequences of a gene family from different species, polynucleotide sequences which are generated in vivo (eg by viruses, by mutator bacteria, by bacteria under UV radiation) or in vitro (eg by means of Q ⁇ -Replicase reaction, faulty PCR) were replicated with a particularly high error rate.
- the polynucleotides used in the method according to the invention can be any polynucleotides, in particular DNA or RNA molecules.
- all methods which lead to the cleavage of a phosphodiester bridge bond between 2 nucleotides in a polynucleotide strand of the double-stranded polynucleotide molecule are suitable for generating the single-strand breaks required in step (b) of the method according to the invention.
- These can be physical or chemical processes (e.g. ultrasound treatment, partial ester hydrolysis).
- Enzymatic methods are particularly suitable for step (b).
- Nucleases for example, are suitable for this.
- the single-strand breaks are introduced by sequence-specific nicking enzymes.
- nicking enzymes V.Bchl from Bacillus chitinosporus, N.BstNBI from Bacillus stearother ophilus, N.BstSEI from Bacillus stearothermophilus, N.CviPII from Chlorella strain NC64A, N.CviQXI from Chlorella strain NC64A, V.EcoDem from E .coli, V.Hpall from Haemophilus parainfluenzae, V.Neal from Nocardia aero-colonigenes and V.Xorll from Xanthomonas oryzae.
- the single-strand breaks can be inserted into the double-stranded polynucleotide molecules by means of sequence-unspecific nicking enzymes. It is possible, for example, to use DNase I from calf pancreas with Mg 2+ as a cofactor (Kunitz, J. Genetic Physiology 33 (1950), 349; Kunitz, J. Genetic Physiology 33 (1950), 363, and Melgac and Goldthwaite, J Biological Chem. 243 (1968), 4409).
- reaction conditions in step (c) are selected depending on the enzymes used.
- step (c) is carried out under conditions which lead to an increased error rate in the new synthesis.
- the error rate of the new synthesis can be selected depending on the desired variants to be generated. Usual error rates are 0.1 x 10 ⁇ 3 to 10 x 10 " 3 , ie 0.01 to 1% error (exchange of 1 to 10 bases in a DNA section of 10,000 bases).
- step (c) It is particularly suitable to carry out step (c) at an error rate of 1 ⁇ 10 -3 to 5 ⁇ 10 -3 , ie 0.1 to 0.5% error, ie there are 1 to 5 bases in a DNA section of 1000 bases exchanged.
- the error rate of DNA polymerase I is 9 ⁇ 10 -5 (Kunkel et al. (1984) J. Biol. Chem. 259: 1539-1545.
- the increase in the error rate when using DNA polymerase I consequently means an error rate greater than 9 x 10 ⁇ 6 .
- the error rate of the new synthesis can in principle e.g. be increased by using mutated DNA polymerase or by choosing the appropriate reaction conditions in step (c).
- the error rate of resynthesis is increased by polymerases with reduced or no proofreading activity.
- the error rate of the new synthesis is increased by different nucleotide concentrations as starting materials.
- concentration of one or more nucleotides can be varied in relation to the other nucleotides.
- a deficit of a nucleotide, in particular of dATP, is preferred in comparison to the other nucleotides. Concentrations of, for example, 200 ⁇ M dGTP, dCTP and dTTP and of 20 to 50 ⁇ M ATP are suitable.
- the error rate of the new synthesis is increased by the addition of nucleotide analogs.
- Deoxyinosinosine triphosphate, 7-desazadesoxyguanosine triphosphate and deoxynucleoside- ⁇ -thio-triphosphate may be mentioned as nucleotide analogs.
- the use of deoxyinosine triphosphate is particularly preferred.
- the error rate of the new synthesis is increased by varying the salt concentration. Suitable for this is, for example, an increase in the Mg + ion concentration to concentrations above 1.5 mM.
- the addition of Mn 2+ ions is also suitable, for example in a concentration range from 0.1 to 1 mM, in particular 0.2 to 0.5 mM.
- the error rate of the new synthesis is determined by adding
- Suitable additives are all substances that increase the error rate, examples include dimethyl sulfoxide, polyethylene glycol or glycerin.
- the additives are particularly preferably added in the following concentrations: DMSO 2 to 10%, PEG 5 to 15%, glycerol> 0 to 30%, preferably 5 to 20%.
- the error rate of the new synthesis is increased by changing the reaction temperature, in particular by increasing the temperature.
- steps (b) and (c) are carried out simultaneously.
- step (d) of the method according to the invention can be done by the production of single-stranded polynucleotide molecules according to step (d) of the method according to the invention.
- Partially double-stranded polynucleotide molecules of the single-stranded polynucleotide molecules provided from step (d) according to step (e) of the method according to the invention can be produced by methods known to the person skilled in the art. It is preferably achieved by hybridizing the homologous sections of the complementary single-stranded polynucleotide molecules.
- Hybridization to double-stranded polynucleotides takes place according to methods known to the person skilled in the art. In particular, it can e.g. can be achieved by combining the single strands and setting reaction conditions that promote the annealing of complementary polynucleotides, e.g. by lowering the temperature and / or lowering the salt concentration.
- step (f) of the method according to the invention a template-directed nucleic acid synthesis is carried out on the basis of the partially double-stranded polynucleotide molecules produced in step (e).
- template-directed nucleic acid synthesis designates the synthesis of a polynucleotide by extending an existing single strand on the basis of the information from a corresponding template strand.
- Any enzyme with template-controlled polynucleotide polymerization activity which is capable of synthesizing polynucleotide strands can be used for the polymer reaction.
- a large number of polymerases from various organisms and with different functions have already been developed. isolated and described.
- temperature stability a distinction is made between thermostable (37 ° C) and thermostable polymerases (75 to 95 ° C).
- polymerases differ with regard to the presence of 5 '-3' - and 3 '-5' exonucleolytic activity.
- DNA-dependent DNA polymerases are the most important polymerases.
- DNA polymerases with a temperature optimum at or around 37 ° C. can be used. These include, for example, the DNA polymerases I from E. coli, T7 DNA polymerase from bacteriophage T7 and the T4 DNA polymerase from bacteriophage T4, each of which is available from a large number of manufacturers, eg USB, Röche Molecular Biochemicals, Stratagene, NEB or Quantum Biotechnologies, are commercially available.
- DNA polymerase I from E. coli holoenzyme
- the enzyme is used for in vitro labeling of DNA using the nick translation method (Rigby et al. (J. Mol. Biol. 113 (1977)), 237-251)).
- the Klenow fragment of DNA polymerase I from E. coli like the T7 DNA polymerase and the T4 DNA polymerase, has a 5 'exonuclease activity.
- These enzymes are therefore used for so-called filling reactions or for the synthesis of long strands (Young et al. (Biochemistry 31 (1992), 8675-8690), Lehman (Methods Enzymol. 29 (1974), 46-53)).
- the 3 '-5' exo (-) variant of the Klenow fragment of DNA polymerase I from E. coli also lacks the 3 'exonuclease activity.
- This enzyme is often used for Sanger DNA sequencing (Sanger (Proc. Natl. Acad. Sci. USA 74 (1977), 5463-5467)).
- Sanger DNA sequencing Sanger (Proc. Natl. Acad. Sci. USA 74 (1977), 5463-5467).
- thermostable DNA polymerase with a temperature optimum at 75 ° C and sufficient stability at 95 ° C is the Taq DNA polymerase from Thermus aquaticus, which is commercially available.
- the Taq DNA polymerase is a highly processive 5 '-3' DNA polymerase without 3 '-5' exonuclease activity. It is often used for standard PCRs, for sequencing reactions and for mutagenic PCRs (Cadwell and Joyce (PCR Methods Appl. 3 (1994), 136-140, Agrogoni and Kaminski (Methods Mol. Biol.
- Tth DNA polymerase from Thermus thermophilus HB8 and the Tfl DNA polymerase from Thermus flavus have similar properties, but the Tth DNA polymerase additionally has an intrinsic reverse transcriptase (RT) Activity in the presence of manganese ions on (Cusi et al.
- RT reverse transcriptase
- thermostable DNA polymerases without 5'- but with 3'-exonuclease activity become commercial distributed: Pwo DNA polymerase from Pyrococcus woesei, Tli, Vent or DeepVent DNA polymerase from Thermococcus litoralix, Pfx or Pfu DNA polymerase from Pyrococcus furiosus, Tub DNA polymerase from Thermus ubiquitous, Tma - or UlTma DNA polymerase from Thermotoga maritima (Newton and Graham, in: PCR, spectrum Akad. Verlag Heidelberg (1994), 1)).
- Polymerases without 3 'proofreading exonuclease activity are used to amplify PCR products as error-free as possible.
- RNA-dependent DNA polymerases include the AMV reverse transcriptase from the Avian myeloblastosis virus, the M-MuLV reverse transcriptase from Moloney Murine leukemia virus, and the HUV reverse transcriptase from the human immunodeficiency virus the most common enzymes, which are also commercially available from various providers such as NEB, Life Technologies, Quantum Biotechnologies.
- the AMV reverse transcriptase has an associated RNase-H activity. This is significantly reduced with the M-MuLV reverse transcriptase. Both M-MuLV and AMV reverse transcriptase lack 3 '-5' exonuclease activity.
- DNA-dependent RNA polymerases include RNA polymerase from E. coli, SP6-RNA polymerase from Salmonella thyphimurium LT2 infected with bacteriophage SP6, T3-RNA polymerase from bacteriophage T3, and T7- RNA polymerase from bacteriophage T7 among the most common enzymes.
- the template strands in step (f) of the method are DNA molecules, and a DNA-dependent DNA polymerase is used for the template-directed single-strand synthesis.
- a non-thermostable DNA polymerase is used, particularly preferably one with 5'- and 3 '-exonucleolytic activity, e.g. Polymerase I from E. coli.
- a non-thermostable DNA polymerase can be used which does not have 5'-1-3 '-exonucleolytic activity, but does have a 3' - + - 5 '-exonucleolytic activity, e.g. the Klenow fragment of DNA polymerase I from E. coli, the T7 DNA polymerase from bacteriophage T7 or the T4 DNA polymerase from bacteriophage T4.
- a non-thermostable DNA polymerase can be used, which has neither 5'-3'- nor 3 '- + - 5' -exonucleolytic activity, such as the 3 '-5' -exo (-) variant of Klenow Fragment of DNA polymerase I from E. coli.
- a thermostable polymerase eg Taq-Pol, Pwo-Pol is used.
- This in turn can have 5 '- and 3' -exonucleolytic activity or 5 '-exonucleolytic activity, but no 3' -exonucleolytic activity such as the Taq-DNA polymerase from Thermus aquaticus, the Tth-DNA polymerase from Thermus thermo - philis HB8 or the Tfl-DNA polymerase from Thermus flavus.
- thermostable DNA polymerase may not have 5 '- + 3' - but 3 '- + 5' exonucleolytic activity, e.g. the Pwo-DNA polymerase from Pyrococcus woesei, the VentR-DNA polymerase, the DeepVentR-DNA polymerase or the Tli-DNA polymerase from Thermococcus litoralis, the Pfu-DNA polymerase or the Pfx-DNA polymerase Pyrococcus furiosus or Tma DNA polymerase or Ulma DNA polymerase from Thermotoga maritima.
- the Pwo-DNA polymerase from Pyrococcus woesei the VentR-DNA polymerase, the DeepVentR-DNA polymerase or the Tli-DNA polymerase from Thermococcus litoralis
- the Pfu-DNA polymerase or the Pfx-DNA polymerase Pyrococcus furiosus or Tma DNA polymerase or Ulma
- thermostable polymerase which has neither 3 '- + 5'- nor 5'-1-3' -exonuclelytic activity, e.g. the Stoffel fragment of the Taq DNA polymerase from Thermus aquaticus, the Tsp DNA polymerase or the exo (-) variant of the VentR-DNA polymerase or DeepVentR-DNA polymerase from Thermococcus litoralis.
- thermostable polymerase the polymerase reaction preferably follows directly on to step (e) without intermediate purification or further sample treatment.
- the matrix strands in step (f) of the method according to the invention on which the template-oriented. Single strand synthesis takes place, RNA molecules.
- an RNA-dependent DNA polymerase is used for the template-directed single-strand synthesis, preferably AMV reverse transcriptase from the Avian myeloblastosis virus, HIV reverse transcriptase from the human immunodeficiency virus, or M-MuLV reverse transcriptase from the Moloney Murine Leukemia Virus.
- a thermostable reverse transcriptase is preferably used, very particularly the Tth DNA polymerase from Thermus thermophilus with intrinsic reverse transcriptase activity. example 1
- LipA H86W encoded by pBP2035 LipA S87T encoded by pBP2008
- LipA F142W encoded by pBP2006 LipA L167A encoded by pBP2007.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003240683A AU2003240683A1 (en) | 2002-05-24 | 2003-05-21 | Method for creating polynucleotide molecules |
MXPA04011554A MXPA04011554A (es) | 2002-05-24 | 2003-05-21 | Generacion de moleculas de polinucleotido. |
CA002485218A CA2485218A1 (en) | 2002-05-24 | 2003-05-21 | Method for creating polynucleotide molecules |
JP2004508297A JP2005529596A (ja) | 2002-05-24 | 2003-05-21 | ポリヌクレオチド分子の製造方法 |
KR10-2004-7018944A KR20050004207A (ko) | 2002-05-24 | 2003-05-21 | 폴리뉴클레오티드 분자의 제조 방법 |
EP03730082A EP1511842A2 (de) | 2002-05-24 | 2003-05-21 | Verfahren zur erzeugung von polynukleotidmolekülen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10223057A DE10223057A1 (de) | 2002-05-24 | 2002-05-24 | Verfahren zur Erzeugung von Polynukleotidmolekülen |
DE10223057.9 | 2002-05-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003100058A2 true WO2003100058A2 (de) | 2003-12-04 |
WO2003100058A3 WO2003100058A3 (de) | 2004-09-02 |
Family
ID=29432268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/005308 WO2003100058A2 (de) | 2002-05-24 | 2003-05-21 | Verfahren zur erzeugung von polynukleotidmolekülen |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1511842A2 (de) |
JP (1) | JP2005529596A (de) |
KR (1) | KR20050004207A (de) |
CN (1) | CN1656221A (de) |
AU (1) | AU2003240683A1 (de) |
CA (1) | CA2485218A1 (de) |
DE (1) | DE10223057A1 (de) |
MX (1) | MXPA04011554A (de) |
WO (1) | WO2003100058A2 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2574197A (en) * | 2018-05-23 | 2019-12-04 | Oxford Nanopore Tech Ltd | Method |
US10927394B2 (en) | 2017-01-19 | 2021-02-23 | Oxford Nanopore Technologies Limited | Methods and reagents for synthesising polynucleotide molecules |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002024953A1 (en) * | 2000-09-21 | 2002-03-28 | Merck & Co., Inc. | Method for generating recombinant polynucleotides |
WO2002079468A2 (en) * | 2001-02-02 | 2002-10-10 | Large Scale Biology Corporation | A method of increasing complementarity in a heteroduplex polynucleotide |
-
2002
- 2002-05-24 DE DE10223057A patent/DE10223057A1/de not_active Withdrawn
-
2003
- 2003-05-21 AU AU2003240683A patent/AU2003240683A1/en not_active Abandoned
- 2003-05-21 MX MXPA04011554A patent/MXPA04011554A/es not_active Application Discontinuation
- 2003-05-21 CA CA002485218A patent/CA2485218A1/en not_active Abandoned
- 2003-05-21 WO PCT/EP2003/005308 patent/WO2003100058A2/de not_active Application Discontinuation
- 2003-05-21 EP EP03730082A patent/EP1511842A2/de not_active Withdrawn
- 2003-05-21 KR KR10-2004-7018944A patent/KR20050004207A/ko not_active Application Discontinuation
- 2003-05-21 CN CNA038119277A patent/CN1656221A/zh active Pending
- 2003-05-21 JP JP2004508297A patent/JP2005529596A/ja not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002024953A1 (en) * | 2000-09-21 | 2002-03-28 | Merck & Co., Inc. | Method for generating recombinant polynucleotides |
WO2002079468A2 (en) * | 2001-02-02 | 2002-10-10 | Large Scale Biology Corporation | A method of increasing complementarity in a heteroduplex polynucleotide |
Non-Patent Citations (1)
Title |
---|
KIKUCHI M ET AL: "An effective family shuffling method using single-stranded DNA" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, Bd. 243, Nr. 1-2, Februar 2000 (2000-02), Seiten 133-137, XP004187682 ISSN: 0378-1119 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10927394B2 (en) | 2017-01-19 | 2021-02-23 | Oxford Nanopore Technologies Limited | Methods and reagents for synthesising polynucleotide molecules |
US11884950B2 (en) | 2017-01-19 | 2024-01-30 | Oxford Nanopore Technologies Plc | Methods and reagents for synthesising polynucleotide molecules |
GB2574197A (en) * | 2018-05-23 | 2019-12-04 | Oxford Nanopore Tech Ltd | Method |
GB2574197B (en) * | 2018-05-23 | 2022-01-05 | Oxford Nanopore Tech Ltd | Double stranded polynucleotide synthesis method and system. |
Also Published As
Publication number | Publication date |
---|---|
DE10223057A1 (de) | 2003-12-11 |
JP2005529596A (ja) | 2005-10-06 |
KR20050004207A (ko) | 2005-01-12 |
WO2003100058A3 (de) | 2004-09-02 |
EP1511842A2 (de) | 2005-03-09 |
MXPA04011554A (es) | 2005-03-07 |
AU2003240683A1 (en) | 2003-12-12 |
CA2485218A1 (en) | 2003-12-04 |
CN1656221A (zh) | 2005-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19953854C2 (de) | Verfahren zur Herstellung von Biopolymeren mit veränderten Eigenschaften | |
DE60112746T2 (de) | Kälteempfindliche dna-polymerasemutanten | |
DE60122962T2 (de) | Reverse Transkription bei hoher Temperatur durch die Verwendung von mutierten DNA Polymerasen | |
US7176025B2 (en) | Methods for generating double stranded DNA comprising a 3′ single stranded portion and uses of these complexes for recombination | |
DE69934088T2 (de) | Verfahren zur in vitro amplifikation zirkulärer dna | |
DE60214864T2 (de) | Verfahren zur herstellung von nukleinsäuren bestehend aus stochastisch kombinierten anteilen von ausgangsnukleinsäuren | |
DE60317693T2 (de) | Methode und verwendung von thermostabilen rna-ligasen | |
DE60300389T2 (de) | Verfahren zur selektiven zufallsmutagenese von polynukleotiden | |
DE60029225T2 (de) | Zusammensetzungen und verfahren zu höhere empfindlichkeit und spezifität von nukleinsäuresynthese | |
DE69730558T2 (de) | Methode zur Bildung makromolekularer Mikrogenpolymeren | |
WO1996005296A1 (de) | Verfahren zur herstellung und amplifikation von nukleinsäuren | |
WO2003100058A2 (de) | Verfahren zur erzeugung von polynukleotidmolekülen | |
DE60202196T2 (de) | Orientationsgerichtete konstruktion von plasmiden | |
WO2002029016A2 (de) | Thermostabile polymerase aus thermococcus pacificus | |
DE10119203B4 (de) | Verfahren zur Erzeugung von doppelsträngigen Nukleinsäuren mit einzelsträngigen Überhängen beliebiger Länge und Nukleotidzusammensetzung | |
DE602004004491T2 (de) | Verfahren zur Herstellung von zirkulären mutierten und/oder chimären Polynukleotiden | |
EP1015640A2 (de) | Verfahren zur synthese und amplifikation von nukleinsäuren | |
DE69832459T2 (de) | Modifizierte DNA Polymerase aus Corboxydothermus hydrogenoformans und deren Verwendung für gekoppelte reverse Transkription und Polymerase-Kettenreaktion | |
JPH0675506B2 (ja) | 試験管内遺伝子合成 | |
DE102005048503A1 (de) | Verfahren zur Steuerung der abschnittsweisen enzymatischen Nukleinsäurevervielfältigung über inkomplette Komplementärstränge | |
DE10234577A1 (de) | Einheitliche Strategie zur Generierung und vielfältigen Rekombination von diversifizierten Oligonukleotiden und DNS - Molekülen zur Funktionsgestaltung von funktionstragenden DNS - Molekülen und ihren Produkten | |
KR20160149158A (ko) | 고집적도 올리고뉴클레오티드 디자인을 통한 유전자 합성 방법 | |
WO2002029095A1 (de) | Verfahren zur mutationsanalyse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003730082 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2485218 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/011554 Country of ref document: MX Ref document number: 2004508297 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047018944 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038119277 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047018944 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003730082 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003730082 Country of ref document: EP |